Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Revenue (2016 - 2026)

Heron Therapeutics filings provide 13 years of Revenue readings, the most recent being $34.7 million for Q1 2026.

  • On a quarterly basis, Revenue fell 10.78% to $34.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $150.7 million, a 1.48% increase, with the full-year FY2025 number at $154.9 million, up 7.36% from a year prior.
  • Revenue hit $34.7 million in Q1 2026 for Heron Therapeutics, down from $40.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $40.8 million in Q4 2024 to a low of $23.5 million in Q1 2022.
  • Median Revenue over the past 5 years was $34.2 million (2023), compared with a mean of $33.4 million.
  • Biggest five-year swings in Revenue: skyrocketed 45.38% in 2022 and later decreased 10.78% in 2026.
  • Heron Therapeutics' Revenue stood at $30.0 million in 2022, then increased by 14.0% to $34.2 million in 2023, then increased by 19.13% to $40.8 million in 2024, then decreased by 0.47% to $40.6 million in 2025, then fell by 14.48% to $34.7 million in 2026.
  • The last three reported values for Revenue were $34.7 million (Q1 2026), $40.6 million (Q4 2025), and $38.2 million (Q3 2025) per Business Quant data.